Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Up Following Earnings Beat

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $31.62, but opened at $34.00. Teva Pharmaceutical Industries shares last traded at $34.5430, with a volume of 4,537,495 shares.

The company reported $0.53 EPS for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 beat — Teva reported $0.53 EPS vs. $0.52 consensus and revenue of $3.98B vs. $3.85B expected; results were driven by branded medicines growth and helped the company top estimates. Teva beats Q1 estimates
• Positive Sentiment: Acquisition announced — Teva will acquire Emalex Biosciences for $700M cash up front (with up to additional contingent consideration) to gain ecopipam, an NDA‑ready, first‑in‑class dopamine D1 antagonist for pediatric Tourette syndrome that has orphan and Fast Track designations and positive Phase 3 data; NDA expected 2H‑2026 — a strategic buy to bolster the neuroscience/innovative portfolio. Teva to Acquire Emalex Biosciences
• Positive Sentiment: Branded product traction — Partnered product UZEDY (Medincell/Teva) posted U.S. net sales of $63M in Q1, up 62% YoY, supporting Teva’s branded growth narrative. Medincell UZEDY Q1 sales
• Positive Sentiment: Market reaction — Coverage notes and headlines highlight a “surge” as investors price in the company’s growth pivot and the Q1 beat. Teva Surges As Its New Growth Strategy Hits A Key Inflection Point
• Neutral Sentiment: Guidance largely in line — FY‑2026 EPS guidance was set at $2.57–$2.77 (consensus ~2.66) and revenue guidance $16.4–$16.8B (consensus ~$16.5B). The range leaves room for execution risk but is not a big negative surprise. Q1 2026 Press Release
• Negative Sentiment: Ongoing generic pressure — Management noted lower revenues from lenalidomide capsules (generic Revlimid) which weighed on sales growth; continued generics erosion remains a watch item for margin and top‑line stability. Q1 results & commentary

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TEVA. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Piper Sandler reissued an “overweight” rating and set a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Scotiabank lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $38.78.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Richard Daniell sold 17,295 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the sale, the executive vice president directly owned 85,755 shares in the company, valued at approximately $2,715,860.85. The trade was a 16.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Brian Savage sold 1,127 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $35,692.09. Following the completion of the sale, the insider owned 10,914 shares of the company’s stock, valued at approximately $345,646.38. This trade represents a 9.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 920,901 shares of company stock valued at $30,056,789. Insiders own 0.54% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. Norges Bank acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after purchasing an additional 6,878,304 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its holdings in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares during the last quarter. Finally, Schroder Investment Management Group lifted its holdings in Teva Pharmaceutical Industries by 261.1% in the 4th quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after purchasing an additional 5,370,253 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 9.2%

The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $39.71 billion, a price-to-earnings ratio of 28.74, a price-to-earnings-growth ratio of 2.75 and a beta of 0.76. The company has a fifty day moving average of $31.12 and a two-hundred day moving average of $29.24.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.